Pharmaceutical giant AstraZeneca is set to purchase a leading biotech firm in a move that highlights the growing trend of corporate consolidation in the industry. The buyout, reportedly worth billions of dollars, is the latest example of Big Pharma's efforts to bolster its drug pipelines and stay ahead of the competition. As the global pharmaceutical market continues to evolve, companies are increasingly turning to biotech firms to tap into cutting-edge research and innovative treatments. With this deal, AstraZeneca aims to strengthen its position in the market and expand its portfolio of life-changing medicines.
Buyout comes amid an uptick in biotech dealmaking as Big Pharma seeks to bolster its drug pipelines
